2026-09-15T18:14:41Zhttps://gredos.usal.es/oai/request

oai:gredos.usal.es:10366/1451932025-04-30T20:48:48Zcom_10366_133043com_10366_4576com_10366_3823col_10366_135272

Jaraíz-Rodríguez, Myriam González-Tablas Pimenta, María Otero Rodríguez, Álvaro Orfao de Matos Correia e Vale, José Alberto Medina Jiménez, José María Tabernero Urbieta, María Aránzazu Tabernero, María Dolores Connexin43 (CX43) Human Glioma Stem Cell Migration [EN] Connexin43 (CX43), a protein that forms gap junction channels and hemichannels in astrocytes, is downregulated in high-grade gliomas. Its relevance for glioma therapy has been thoroughly explored; however, its positive effects on proliferation are counterbalanced by its effects onmigration and invasion. Here,weshowthat a cell-penetrating peptide based onCX43(TAT-Cx43266-283) inhibited c-Src and focal adhesion kinase (FAK) and upregulated phosphatase and tensinhomolog inglioma stem cells (GSCs) derived from patients. Consequently, TAT-Cx43266-283 reduced GSC motility, as analyzed by time-lapse microscopy, and strongly reduced their invasive ability. Interestingly, we investigated the effects of TAT-Cx43266-283 on freshly removed surgical specimens as undissociated glioblastoma blocks, which revealed a dramatic reduction in the growth, migration, and survival of these cells. In conclusion, a region of CX43 (amino acids 266–283) exerts an important anti-tumor effect in patient-derived glioblastoma models that includes impairment of GSC migration and invasion. 2021-02-09 2021-02-09 2017 info:eu-repo/semantics/article Jaraíz Rodríguez, M.; Tabernero, M.D. [et al.] (2017). A short region of Connexin43 reduces human glioma stem cell migration, invasion, and survival through Src, PTEN, and FAK. Stem Cell Reports, 9(2), pp. 451-463. doi:10.1016/j.stemcr.2017.06.007 2213-6711 http://hdl.handle.net/10366/145193 10.1016/j.stemcr.2017.06.007 eng https://doi.org/10.1016/j.stemcr.2017.06.007 http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional Stem Cell Reports